While IL-17A blockade is successful in diminishing disease in patients with plaque psoriasis and ankylosing spondylitis, treatment of CD patients with IL-17A-blocking antibodies surprisingly enhanced disease severity resulting in a premature end to these clinical trials (101, 102). Here, IL17A is linked to psoriasis vulgaris.